Drug Profile
Inclisiran - Alnylam Pharmaceuticals/Novartis
Alternative Names: ALN-60212; ALN-PCSsc; KJX-839; Leqvio; PCSK9siLatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Novartis
- Class Amides; Amino sugars; Antihyperlipidaemics; Cardiovascular therapies; Drug conjugates; Small interfering RNA; Vascular disorder therapies
- Mechanism of Action PCSK9 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypercholesterolaemia
- Registered Hyperlipidaemia
- Phase III Cardiovascular disorders; Coronary artery disease
Most Recent Events
- 07 Feb 2024 Novartis intends to submit first regulatory application for Hypercholesterolaemia (primary prevention of cardiovascular events) in or after 2027 (Novartis pipeline, February 2024)
- 08 Jan 2024 Novartis intends to submit first regulatory application for Hypercholesterolaemia (In children, In infants, In adolescents) by or in 2027 (Novartis pipeline, February 2027)
- 25 Sep 2023 Registered for Hypercholesterolaemia in Japan (SC)